S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Nolla Health Bolsters Clinical Oversight for AI-Driven Platform

Harvard-trained physician Dr. Zaid Fadul has joined Nolla Health’s medical advisory board, marking a strategic push to ground the company’s AI-first healthcare tools in rigorous clinical practice. The move comes as Nolla expands its oversight team to ensure patient safety and diagnostic accuracy across its digital platforms.

Nolla Health Bolsters Clinical Oversight for AI-Driven Platform
Photo: Bio & News

Dr. Fadul, who also serves as CEO of Bespoke Concierge MD, joins existing board members Dr. Omar Badri and Dr. Michael Mina to refine the company’s approach to responsible AI. The expansion includes new clinical oversight from emergency medicine specialist Dr. Michael Policastro and Chief Medical Officer Dr. Michael Ednie. These appointments aim to bridge the gap between technological innovation and traditional medical judgment, ensuring that tools like the Nolla Skin selfie-analysis system remain tethered to evidence-based standards.

Beyond advising on protocols, Nolla Health plans to launch an educational initiative with Dr. Fadul to explore the ethics and practical implementation of AI in medicine. CEO Luis Wenus stated that the company’s objective is to integrate artificial intelligence with human expertise to improve patient outcomes. As the platform scales its services across more than 40 states, the emphasis remains on maintaining physician-led quality control in the evolving digital healthcare landscape.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!